Have an Account?

Email address should not be empty!

Email address should not be empty!

Forgot your password?

Close

First Name should not be empty!

Last Name should not be empty!

Last Name should not be empty!

Email address should not be empty!

Show Password should not be empty!

Show Confirm Password should not be empty!

Error message here!

Back to log-in

Close

Aleph Farms appoints Yifat Gavriel as Chief of Regulatory Affairs Ahead of global commercialisation

Gavriel will play a critical role in the introduction of Aleph Farms’ novel products into global markets Aleph Farms, the first cultivated meat company to grow steaks directly from non-genetically engineered animal cells, has announced the addition of Yifat Gavriel as Chief of Regulatory Affairs and Quality Assurance. In this position, Gavriel will play a […]

Aleph Farms appoints Yifat Gavriel as Chief of Regulatory Affairs Ahead of global commercialisation

Gavriel will play a critical role in the introduction of Aleph Farms’ novel products into global markets

Aleph Farms, the first cultivated meat company to grow steaks directly from non-genetically engineered animal cells, has announced the addition of Yifat Gavriel as Chief of Regulatory Affairs and Quality Assurance. In this position, Gavriel will play a critical role in the introduction of Aleph Farms’ novel products into global markets. The establishment of a regulatory approval process for cultivated meat is underway in many countries around the world, with the Singapore Food Agency the first to approve it as an ingredient in 2020.

Didier Toubia, CEO and co-founder of Aleph Farms said, “In our work with regulatory agencies around the world, we have seen first-hand how they encourage innovation and have been willing to continue transparent dialogues with us and the wider cultivated meat industry. The next 6-12 months will prove critical as we work closely with regulators to launch our first product in key markets.”

Gavriel joins after previously serving as the head of regulatory affairs at Omrix Biosurgery Israel (a Johnson & Johnson subsidiary), where she managed the entire biological portfolio end-to-end, including biological products, combination products and medical device products.

Leave a Comment

Newsletter

Stay connected with us.